Oral Presentations 10- Pharmacometrics

16:00 • 750 • The use of artificial nonparametric pharmacokinetic quasi-models for managing intravenous piperacillin therapy in critically ill adults with unstable physiology > G. Gellert Balazs Karvaly 16:13 • 718 • Does Nonlinear Absorption of Oral Misoprostol Challenge Guideline-Based Dosing in Late Pregnancy Cervical Ripening? A Population Pharmacokinetic Model to Resolve. > Z. Zhiyuan TAN 16:26 • 618 • A physiologically-based pharmacokinetic model for intraperitoneal irinotecan to evaluate the impact of UGT1A1 variability on SN-38 exposure > S. Stijn Koolen 16:39 • 602 • Age-Related Differences in Systemic and Brain Exposure to Elexacaftor-Tezacaftor-Ivacaftor: A PBPK Modeling Study in Pediatric and Adult Cystic Fibrosis > C. Clotilde Vellat 16:52 • 160 • Biomarker and Dosing Insights from Quantitative Systems Pharmacology for nivolumab–ipilimumab in Advanced Hepatocellular Carcinoma > L. Lin Yang 17:05 • 341 • An evaluation of different performance metrics for assessing model accuracy in a priori and Bayesian forecasting in pharmacometrics > S. Sebastian G. Wicha 17:18 • 1 • Plasma Does Not Forget: From Stochastic Reconstruction to Distribution-Based Inference in PopPK Adherence Detection > M. Manel Filali